Journal of Antimicrobial Chemotherapy (2002) 49, 999-1005
© 2002 The British Society for Antimicrobial Chemotherapy
Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials
Department of Epidemiology MC-45, Albany Medical Center Hospital, 43 New Scotland Avenue, Albany, NY 12208, USA
Received 9 May 2001; returned 31 October 2001; revised 10 December 2001; accepted 25 January 2002.
Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen worldwide. To investigate an association between antimicrobial use and MRSA, a case control study of 121 patients infected with MRSA compared with 123 patients infected with methicillin-susceptible S. aureus (MSSA) was carried out. Antimicrobial use was analysed by three different logistic regression models: all ß-lactam antibiotics, ß-lactam antibiotics grouped in classes and antimicrobial use in grammes. Patients infected with MRSA tended to have more co-morbidities, longer lengths of stay (LOS) and greater exposure to antibiotics than MSSA-infected patients. Multivariate analysis identified levofloxacin [odds ratio (OR) 8.01], macrolides (OR 4.06), previous hospitalization (OR 1.95), enteral feedings (OR 2.55), surgery (OR 2.24) and LOS before culture (OR 1.03) as independently associated with MRSA infection. All models were concordant with the exception of macrolides, which were not significant based on the number of grammes administered. There were no significant differences in the types of infection or the attributed mortality in either group. MRSA-infected patients had a significantly longer LOS before infection [18.8 ± 18.2 compared with 8.4 ± 6.9 (P < 0.001)] and a significantly longer post-diagnosis LOS [27.8 ± 32.9 compared with 18.6 ± 21 (P = 0.01)] than MSSA-infected patients.
* Corresponding author. Tel: +1-518-262-8230; Fax: +1-518-262-3745; E-mail: Graffue{at}mail.amc.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii15 - iii23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nathwani, M. Morgan, R. G. Masterton, M. Dryden, B. D. Cookson, G. French, D. Lewis, and on behalf of the British Society for Antimicrobial Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community J. Antimicrob. Chemother., May 1, 2008; 61(5): 976 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tacconelli, G. De Angelis, M. A. Cataldo, E. Pozzi, and R. Cauda Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis J. Antimicrob. Chemother., January 1, 2008; 61(1): 26 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Goff and M. J. Dowzicky Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial J. Med. Microbiol., September 1, 2007; 56(9): 1189 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. French Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin J. Antimicrob. Chemother., December 1, 2006; 58(6): 1107 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bosso and P. D. Mauldin Using Interrupted Time Series Analysis To Assess Associations of Fluoroquinolone Formulary Changes with Susceptibility of Gram-Negative Pathogens and Isolation Rates of Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2106 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. MacDougall and R. E. Polk Antimicrobial Stewardship Programs in Health Care Systems Clin. Microbiol. Rev., October 1, 2005; 18(4): 638 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and the Linezolid CSSTI Study Group Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2260 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.B. Bamford, S. Wood, and R.J. Shaw Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust QJM, February 1, 2005; 98(2): 75 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Hardy, P. M. Hawkey, F. Gao, and B. A. Oppenheim Methicillin resistant Staphylococcus aureus in the critically ill Br. J. Anaesth., January 1, 2004; 92(1): 121 - 130. [Abstract] [Full Text] [PDF]
|
|